anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This Phase 1 dose escalation study will evaluate safety and immunogenicity of both non-adjuvanted and adjuvanted VEE VLP vaccine in three dose groups (2 μg, 10 μg, and 20 μg) given as a 2-dose primary series IM injection (Days 0 and Week 4 \[Day 28\]) followed by a booster dose injection (Week 20 \[Day 140\]). Each group will consist of 30 subjects, for a total of 90 study subjects. Each group of 30 subjects will be randomized to receive either non-adjuvanted vaccine (Subgroup A; n=15) or adjuvanted vaccine (Subgroup B; n=15). Subjects will be blinded to receiving the non-adjuvanted versus adjuvanted vaccine, but will not be blinded to the vaccine dosage. Enrollment will utilize a sentinel dose design, with only one subject receiving a vaccine dose the initial day, 2 subjects the following day, and 3 subjects the subsequent day, before proceeding with further enrollments in that group. Subjects in each Group will be randomized to receive the vaccine dose either without adjuvant (Subgroup A) or with adjuvant (Subgroup B).
FIELD: steroid compounds. SUBSTANCE: product: proposed stable crystals of 14a-hydroxy-4-androstene-3,6,17-trione show biological activity. They inhibit enzyme activity taking part in human placenta estrodiene synthesis. These crystals consist of two crystal types exhibiting characteristic peaks based on the data obtained by crystalline powder diffraction pattern using roentgen rays analysis. Also, methods of these crystals preparing were described. EFFECT: improved method of crystals preparing.
Studies have shown that mTOR inhibitors (MTI) inhibit growth of pre-B and T-cell ALL cell lines in vitro and in ALL xenograft models. The MTI temsirolimus was chosen for use in this study due to its weekly intravenous dosing, its more predictable blood levels, and availability of a single-agent pediatric MTD and its sustained biologic effect due to conversion to sirolimus. This study will determine the maximum tolerated dose of temsirolimus that can given in combination with dexamethasone, cyclophosphamide and etoposide in relapsed ALL, LL or PTL. A standard 3-patient cohort dose-escalation design will be used. Response to treatment will be evaluated. Biology tests will be done to evaluate minimal residual disease (MRD), temsirolimus' effect on glucocorticoid resistance, and mTOR inhibition.
Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
Immune thrombocytopenia (ITP) is due to autoantibodies against platelet surface antigens. ITP is considered as either primary, with no clear etiology, or as secondary ITP (drug-induced; underlying diseases). Autoantibodies lead both to loss of platelets in the spleen and/or liver but simultaneously reduce their production. Contrary to other disorders with thrombocytopenia, ITP has reduced levels of thrombopoetin. ITP remains a diagnosis of exclusion. A single defining laboratory test does not exist. Glycoprotein-specific antibodies can be detected in only about 50% of cases. Ruling out EDTA-induced pseudo thrombocytopenia is of particular relevance. Secondary causes of thrombocytopenia should be excluded through medical history (especially medication history), physical examination and possibly bone-marrow puncture.
PURPOSE: To provide an effective photoaging-prevention agent having high safety and provide a skin cosmetic having excellent skinbeautifying effect and safely usable without damaging the skin. CONSTITUTION: This photoaging-prevention agent is composed of one or more kinds of substances selected from oleanolic acid (3β-hydroxyolean-12-en-28-oic acid), its salt and an oleanolic acid derivative. Oleanolic acid is a kind of ursane-type triterpenoid widely distributing in the vegetable kingdom and easily separable from a plant by using conventional organic solvent (e.g. alcohol). The oleanolic acid derivative is e.g. acyloleanolic acid or its ester derivative preferably having a 2-20C acyl group and a 1-20C alkyl group. The amount of the photoaging-prevention agent to be compounded to a skin cosmetic is 0.001-10wt.%, preferably 0.01-1wt.% based on the total cosmetic.
An organic sol-gel nano-composition containing three solid lipid nano-components loaded with phytochemical active ingredients is proposed. Panax notoginseng saponins are extracted from Vietnamese Panax notoginseng. Rutin is extracted from Styphnolobium japonicum in Thai Binh Province, Vietnam, and Ginkgo biloba is extracted from Ginkgo biloba trees. The composition has shown to have low toxicity and great bioavailability. In particular, the composition is effective against local myocardial ischemias and arrhythmias, improves the blood rheology, platelet circulation and antiaggregation, and thrombosis, lowers the blood lipids to a certain limit, and has good effects against atherosclerosis. The composition has an antioxidant effect of preventing free radical damages, and has an effect of enhancing capillary resistance, strengthening the vessel walls that reduces hypertension risks, which accordingly protects the cerebral nerves, prevents strokes, and is also used to recover after strokes and other hemorrhagic diseases for the enhancement effects and reconstruction of the damaged blood vessels.
A moringa extract for promoting collagen secretion and application thereof belong to the technical field of plant extracts and application thereof. Pulverizing Moringa oleifera raw material, adding deionized water, adding at least one protease and at least one cellulase, adding an organic solvent, performing reflux extraction and water enzymolysis under stirring, separating an upper organic phase under the condition that the vacuum degree is not lower than 0.04MP, and performing sealed anaerobic fermentation on the rest material system. The fermentation strain is composed of at least one kind of Saccharomyces cerevisiae and at least one kind of organic acid producing strain. Then carrying out solid-liquid separation of the system, and carrying out ultrafiltration membrane filtration on the liquid phase to obtain an extracting solution. The obtained moringa oleifera extract improves the content of necessary components for generating collagen, has good antioxidant activity and has the condition of promoting collagen secretion. Experiments show that the product of the invention can obviously promote the secretion of collagen. The application is as raw material for preparing cosmetics, health products, medicines or feeds.
Lung cancer is a common malignant tumor that poses a serious threat to human health. Small cell lung cancer accounts for about 20% of lung cancer. Precision medicine has recently been perfectly interpreted in many tumor types, but the treatment of small cell lung cancer is still bleak. The EC/EP regimen is the most classic chemotherapy regimen for small cell lung cancer with good results but is prone to drug resistance. In 2018, with the development of immunotargeting therapy, small molecule multi-target anti-angi drugs, PARP inhibitors, new chemotherapy drugs, etc., the treatment of small cell lung cancer has ushered in a new dawn. As a kind of highly selective multi-target anti-angiogenic TKI drugs,Anlotinib Hydrochloride is a kind of 1.1 innovative drugs with independent intellectual property rights in China, mainly acting on VEGFR, PDGFR, FGFR and c-Kit. The latest ALTER1202 study confirms that anlotinib is significantly improved for PSC and ORR in SCLC patients who have previously received at least 2-line chemotherapy. OS data is not yet mature, but the benefits of the anlotinib group were observed. The adverse effects of anlotinib were consistent with expectations, no new adverse events were found, and safety was tolerated. Nowadays, the effective combination of traditional chemical therapy with molecular targeting and immunotherapy is the future development direction of lung cancer treatment. Therefore, this topic is designed to combine the efficacy of safety and safety with the treatment of anlotinib with the classic EC/EP chemotherapy regimen. Expected to get longer PFS and OS for patient benefit.
The invention provides a system for administering to or through the skin of the individual selected medicaments. The system includes an orthosis and a pad. The pad includes at least one delivery station suitable for containing the medicament. The pad may be positioned in a variety of configurations on the band dependant upon the body part to which the orthosis is applied. Additionally, the pad may comprise a plurality of delivery stations to enhance the spatial and/or temporal parameters for medicament delivery. Also provided is a method for delivering a medicament to or through a selected location of the skin of an individual comprising the steps of attaching to the individual the delivery system of the invention such that the medicament is delivered to or through the skin of the individual.
The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
This study presents the first definitive confirmation of microplastic presence in the human stomach, based on samples from 26 cadavers. 97 microplastic particles were extracted from stomach contents, across all 26 individuals, revealing a universal prevalence of microplastics in the cadavers. Morphological analysis of the extracted particles unveiled distinct shapes, with fibers constituting the majority (52.04 %), followed by fragments (39.80 %) and films (8.16 %). The average quantity of microplastics per individual was calculated to be 9.4 ± 10.4 particles, with an estimated daily intake of microplastics at 32.2 particles per day. These figures are lower than estimates derived from both daily microplastic consumption alone and notably, those calculated from stool analyses. Our study also suggests that the breakdown or transformation of microplastics cannot be ruled out during their passage through the digestive tract. Although the number of microplastics in stomach contents reported in this study was even lower than the daily microplastic intake rates reported in the literature, it provides conclusive evidence for the presence of microplastics in the human stomach and provides important preliminary data in terms of the risks that may arise for human health.
Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
Off-pump coronary artery bypass grafting (OPCAB) is an established alternative to on-pump coronary artery bypass grafting (CABG). OPCAB determines a pro-coagulant state potentially deleterious on grafts patency, that is not counterbalanced by the adverse effects of cardiopulmonary bypass on coagulation occurring in CABG, and that lasts as long as one month. Therefore in OPCAB systemic heparinization is necessary to prevent thrombotic complications during transitory occlusion of coronary arteries and grafts. An internationally accepted standard intra-operative anticoagulation protocol for OPCAB has not yet been defined, and heparinization in OPCAB is a highly variable practice. The intraoperative anticoagulation regimen adopted in patients undergoing OPCAB may influence major postoperative outcomes, such as bleeding, transfusion requirements, inflammatory response, myocardial ischemia and grafts patency, but it has never been the object of large-scale randomized controlled trial (RCT). The 2 most widespread intraoperative anticoagulation protocols in OPCAB are represented by full (300 U/kg) or half (150 U/kg) heparinization, with target ACT ranging from 200 sec to \>480 sec.

Patients enrolled in the study will be randomized to receive full or half heparinization in a 1:1 ratio using a randomization schedule blocked by site. Randomization will take place in the operatory room by the anesthesiologist, and will be blinded to the surgeon.
Sumavel DosePro contains sumatriptan succinate, a selective 5-HT1B/1D receptor agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure:

The empirical formula is C14H21N3O2S•C4H6O4, representing a molecular weight of 413.5. Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline. 

Sumatriptan solution is a clear, colorless to pale yellow, sterile, nonpyrogenic solution for subcutaneous delivery. Each 0.5 mL of Sumavel DosePro 8 mg/mL solution contains 4 mg of sumatriptan (base) as the succinate salt and 3.8 mg of sodium chloride, USP in Water for Injection, USP. Each 0.5 mL of Sumavel DosePro 12 mg/mL solution contains 6 mg of sumatriptan (base) as the succinate salt and 3.5 mg of sodium chloride, USP, in water for injection, USP. The pH range of both solutions is approximately 4.2 to 5.3. The osmolality of both solutions is 291 mOsmol.

Sumavel DosePro is a pre-filled, single-use, disposable, needle-free subcutaneous delivery system delivering sterile sumatriptan injection. Sumavel DosePro consists of the following components: a gray plastic handle and snap-off tip, a lavender (4 mg) or green (6 mg) lever, and a glass medication chamber that is pre-filled with 4 mg or 6 mg per 0.5 mL sumatriptan injection. Utilizing pressure from a compressed nitrogen gas source in the handle, Sumavel DosePro delivers the medication by pushing it through a small, precise hole in the glass medication chamber. The resulting stream of medication is propelled through the skin and is delivered subcutaneously without a needle, following a biphasic pressure profile.
<P>PROBLEM TO BE SOLVED: To provide a flow control element which can be implanted.  <P>SOLUTION: A device 20 is to control the flow of the fluid in a pulmonary passage, and has a body and a valve connected to the body. Here, the valve prevents the fluid from entering into the isolated portion of the patient's lung, but is formed so that the expiration fluid can pass through the valve, and opens by the pressure difference of 10 inches water. The flow control element 22 can permit air to escape from the isolated portion so that the element acts like a valve. A system for implanting the pulmonary device 20 is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: Esophagectomy is the standard of care for curative esophageal cancer. However, it is associated with significant morbidity and mortality. Esophageal cancer is known to negatively affect the nutritional status of patients and many manifest cancer sarcopenia. At present, measures of sarcopenia involve complex and often subjective measurements. We assess whether the Psoas Muscle Index (PMI); an inexpensive, simple, validated method used to diagnose sarcopenia, can be used to predict adverse outcomes in patients after curative esophagectomy.
METHODS: Multi-centre, retrospective cohort between 2010-2020, involving all consecutive patients undergoing curative esophagectomy for esophageal cancer in University Malaya Medical Centre, Sungai Buloh Hospital, and Sultanah Aminah Hospital. The cut-off value differentiating low and normal PMI is defined as 443mm2/m2 in males and 326326 mm2/m2 in females. Complications were recorded using the Clavien-Dindo Scale.
RESULTS: There was no statistical correlation between PMI and major post-esophagectomy complications (p-value: 0.495). However, complication profile was different, and patients with low PMIs had higher 30-day mortality (21.7%) when compared with patients with normal PMI (8.1%) (p-value: 0.048).
CONCLUSIONS: Although PMI did not significantly predict post-esophagectomy complications, low PMI correlates with higher 30-day mortality, reflecting a lower tolerance for complications among these patients. PMI is a useful, inexpensive tool to identify sarcopenia and aids the patient selection process. This alerts healthcare professionals to institute intensive physiotherapy and nutritional optimization prior to esophagectomy.
<P>PROBLEM TO BE SOLVED: To provide a hospital information system for accurately grasping even the case of a medical practice which takes time.  <P>SOLUTION: A sub-system 4A provided with a non-portable PC terminal 6 for performing order registration or the like, and a PDA system 4B provided with a portable PDA 8 capable of inputting and outputting data, are connected to a hospital internal information management system 2 for managing information in a hospital, through a LAN 3. A nurse refers to a work schedule list of instillation or the like set in a work schedule, by carrying the PDA 8, and performs work of starting the scheduled instillation at the place of a patient at the bedside which is a practice place. After the practice of the work, the nurse inputs the practice which is accurately registered in a database of the hospital internal information management system 2, and this information can be rapidly obtained even at the occurrence of such a situation that the actual starting time is put off from the scheduled time. Subsequent work scheduled practices can thereby be easily coped with.  <P>COPYRIGHT: (C)2004,JPO
Participant takes part of the unit´s program with an addition of eVIS. eVIS consists of objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
BACKGROUND: Investigating the prevalence of the coronavirus disease 2019 (COVID-19) infection in asymptomatic children who have been in close contact with symptomatic individuals is instrumental for refining public health approaches, protecting vulnerable populations, and mitigating the broader impact of the pandemic. Accordingly, this study aimed to evaluate the incidence of COVID-19 infection in asymptomatic children who had been in close contact with parents exhibiting COVID-19 symptoms. Study Design: A cross-sectional study.
METHODS: The present cross-sectional study was conducted on 175 asymptomatic children who had been in close contact with COVID-19 confirmed cases in Hamadan County from March 2021 to August 2021. Reverse transcription polymerase chain reaction (RT-PCR) testing was performed on all asymptomatic children who had been in close contact with an individual with COVID-19. Furthermore, multiple logistic regressions were conducted to determine the predictors of COVID-19 transmission from family members to children.
RESULTS: Out of the 175 children in close contact with index cases, 53 (30.29%) tested positive for COVID-19 through PCR. Regarding factors related to the index case, male cases (Adjusted odds ratio [AOR]=2.29; 95% confidence interval [CI]: 1.03-5.09, P=0.041), rural dwellers (AOR=3.22; 95% CI: 1.02-10.16, P=0.046), illiterate cases (AOR=8.45; 95% CI: 1.76-40.65, P=0.008), and cases presenting with nasal congestion symptoms (AOR=9.12; 95% CI: 2.22-37.40, P=0.002) were more prone to transmitting the virus to children who had close contact with them.
CONCLUSION: The findings of the present study suggested that asymptomatic COVID-19 infection in household contacts is significant in children who were in close contact with a COVID-19-positive patient. Therefore, it is crucial to continue to monitor this group closely.
BACKGROUND: Ischemic optic neuropathy (ION) is exceedingly rare in children on dialysis, resulting from poor perfusion of the optic nerve, and presents as sudden acute painless vision loss.
CASE-DIAGNOSIS/TREATMENT: We report the case of a 3-year-old male with stage 5 chronic kidney disease (CKD 5) due to focal segmental glomerulosclerosis (FSGS) status post-bilateral nephrectomy on chronic hemodialysis who had acute loss of vision several hours after a hemodialysis session. Earlier that day, he had a drop in blood pressure intra-dialysis to 89/67 mmHg, with at home blood pressures ranging 90/60 to 150/100 mmHg. The patient was treated with tight blood pressure control to maintain blood flow and prevent blood pressure lability, received high-dose corticosteroids with a corticosteroid taper, and placed on high-dose erythropoietin for neuroprotective effect. He regained partial vision beginning approximately 1 month after presentation.
CONCLUSIONS: The exact cause of our patient's simultaneous bilateral anterior and posterior ION, confirmed via MRI and fundoscopic examination, is unclear; however, is likely secondary to a combination of fluctuating blood pressure, anemia, anephric status, and hemodialysis. This highlights the need for close blood pressure monitoring, management of anemia, and more diligent ophthalmologic screening in pediatric patients on chronic hemodialysis.
PURPOSE:To obtain the titled emulsion by adding a specific radically polymerizable monomer and an ultraviolet absorber to an emulsion of an emulsion-polymerized polymer which may contain an ultra-violet absorber and carrying out the emulsion polymerization of the monomer. CONSTITUTION:An emulsion of an emulsion-polymerized polymer is added with at least one kind of radically polymerizable monomer [e.g. carboxyl- containing monivinyl monomer (a non-film-forming resin capable of improving water resistance, etc., can be produced by using acrylic acid, etc., in an amount of <5wt% of the whole monomer), monovinyl ether, polyfunctional crosslinking monomer, etc. - or + capable of forming a polymer having a contact angle to water of larger than that of the emulsion polymer by 1-110 deg.. The emulsion is emulsion-polymerized to obtain an emulsion of a non-film-forming resin having small pores in the resin and containing an ulraviolet absorber (e.g. 2-ethylhexyl- p-dimethylaminobenzoate). The emulsion prevents transient dermatic stimulation, has high safety and contains the ultra-violet absorber in stable state.